RxDoctor Payments Data

Stephen Giorgianni, DO

Family Medicine · Melbourne, FLNPI 1609182690

Payments from drug & device makers

$1,592in general payments, 2019–2025

Across 75 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$475
  • Novo Nordisk$373
  • Boehringer Ingelheim$140
  • Pfizer$104
  • Qorumpartners$82
  • Exact Sciences$75
  • plus $343 from 10 others

What the payments were for

  • Food & beverage$1,587100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,592 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$61,360
Medicare patients
172
Services billed
1,297

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban41$51,270
TivicayDolutegravir Sodium11$47,560
JardianceEmpagliflozin16$26,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$21,969
XareltoRivaroxaban11$8,066
TradjentaLinagliptin12$5,589
Wixela InhubFluticasone Propion/Salmeterol15$2,930
Ritonavir14$2,618
Pregabalin14$2,232
Rosuvastatin Calcium183$2,164
Atorvastatin Calcium148$1,137
Albuterol Sulfate HfaAlbuterol Sulfate31$970
Levothyroxine Sodium62$967
Celecoxib13$784
Potassium Chloride31$681

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$104$51,27041 claims
Boehringer IngelheimJardiance, Tradjenta$140$31,66828 claims
GSKTrelegy Ellipta$26$21,96918 claims
Johnson & JohnsonXarelto$475$8,06611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →